Viking Global Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,532,119
Closed -$51.1M 97
2025
Q3
$51.1M Sell
2,532,119
-9,149,214
-78% -$161M 0.13% 72
2025
Q2
$196M Buy
11,681,333
+1,555,855
+15% +$25.1M 0.57% 57
2025
Q1
$156M Buy
10,125,478
+3,621,993
+56% +$64.7M 0.49% 59
2024
Q4
$143M Sell
6,503,485
-1,064,048
-14% -$19.4M 0.46% 54
2024
Q3
$136M Buy
+7,567,533
New +$132M 0.5% 53
2016
Q4
Sell
-19,684,219
Closed -$906M 77
2016
Q3
$906M Sell
19,684,219
-8,052,436
-29% -$420M 3.91% 6
2016
Q2
$1.39B Sell
27,736,655
-5,234,967
-16% -$279M 5.92% 4
2016
Q1
$1.76B Buy
32,971,622
+7,927,847
+32% +$465M 7.77% 3
2015
Q4
$1.64B Buy
25,043,775
+16,171,125
+182% +$999M 6.2% 4
2015
Q3
$501M Buy
+8,872,650
New +$575M 1.92% 16
2015
Q2
Sell
-228,600
Closed -$14.2M 68
2015
Q1
$14.2M Buy
+228,600
New +$13.3M 0.06% 55

Other funds holding TEVA

Viking Global Investors's TEVA Position: Q4 2025 in Review

Viking Global Investors sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 2,532,119 shares — an estimated $51.1M sold.

Viking Global Investors first reported a position in TEVA in Q1 2015 and held it in 11 quarters. The position peaked at $1.76B in Q1 2016. 629 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Viking Global Investors reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Viking Global Investors sold 2,532,119 Teva Pharmaceuticals shares in Q4 2025, an estimated $51.1M.
  • Viking Global Investors first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Viking Global Investors's Teva Pharmaceuticals position peaked at $1.76B in Q1 2016.
  • 629 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Viking Global Investors's 13F filing for Q4 2025, filed 17 Feb 2026.